Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MBIO Stock Forecast 2026-2027
$0.70
Current Price
$5.27M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MBIO Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
MBIO Price Momentum
-6.7%
1 Week Change
0.0%
1 Month Change
-39.7%
1 Year Change
-28.6%
Year-to-Date Change
-90.1%
From 52W High of $7.00
+31.1%
From 52W Low of $0.53
📊 TOP ANALYST CALLS
Did MBIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Mustang Bio is one of their latest high-conviction picks.
Latest MBIO Stock Price Targets & Analyst Predictions
MBIO has shown a year-to-date change of -28.6% and a 1-year change of -39.7%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MBIO. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MBIO Analyst Ratings
1
Buy
0
Hold
0
Sell
MBIO Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.70
Latest MBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 16, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $2.00 |
| May 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $2.00 |
| Aug 24, 2023 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $18.00 |
| Aug 16, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $25.00 |
| Aug 15, 2023 | BTIG | Justin Zelin | Buy | Maintains | $16.00 |
| Aug 15, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $25.00 |
| Jun 16, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $25.00 |
| Jun 16, 2023 | BTIG | Justin Zelin | Buy | Maintains | $20.00 |
| May 15, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Mar 30, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $7.00 |
| Nov 16, 2022 | BTIG | Justin Zelin | Buy | Maintains | $4.00 |
| Jan 24, 2022 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $6.00 |
| May 18, 2021 | BTIG | Buy | Initiates | $N/A | |
| Oct 2, 2020 | B. Riley Securities | Buy | Initiates | $N/A | |
| Oct 2, 2020 | B. Riley FBR | Buy | Initiates | $N/A | |
| May 12, 2020 | Oppenheimer | Outperform | Maintains | $13.00 | |
| Aug 13, 2019 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Aug 13, 2019 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Jun 21, 2019 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Dec 21, 2017 | Oppenheimer | Outperform | Initiates | $N/A |
Mustang Bio Inc. (MBIO) Competitors
The following stocks are similar to Mustang Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Mustang Bio Inc. (MBIO) Financial Data
Mustang Bio Inc. has a market capitalization of $5.27M with a P/E ratio of 0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -44.6%.
Valuation Metrics
Market Cap
$5.27M
Enterprise Value
$-10,984,057
P/E Ratio
0.6x
PEG Ratio
-2.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+308.3%
Current Ratio
2.1x
Debt/Equity
0.0x
ROE
-44.6%
ROA
-12.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Mustang Bio Inc. (MBIO) Business Model
About Mustang Bio Inc.
What They Do
Develops innovative therapies for cancer treatment.
Business Model
The company generates revenue through the development and commercialization of proprietary cell and gene therapies, specifically focusing on CAR-T cell therapies and gene therapies. Mustang Bio collaborates with academic institutions and research partners to enhance its R&D efforts, which supports its pipeline of targeted treatments for various cancers and genetic diseases.
Additional Information
Operating in the rapidly evolving biotechnology sector, Mustang Bio addresses significant unmet medical needs by bringing transformative therapies from the laboratory to clinical application. Its focus on innovative treatment solutions positions it as a vital player in improving patient care and outcomes in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4
CEO
Dr. Manuel Litchman M.D.
Country
United States
IPO Year
2017
Website
www.mustangbio.comMustang Bio Inc. (MBIO) Latest News & Analysis
Latest News
This BlackRock stock just spiked over 300%
10 months ago
Quick Summary
Mustang Bio (NASDAQ: MBIO) shares rose sharply following FDA approval, indicating positive investor sentiment.
Why It Matters
FDA approval can lead to increased revenue potential and market confidence, driving share prices up and attracting more investors to Mustang Bio.
Source: Finbold
Market Sentiment:
Positive
Dow Dips 1%; Mustang Bio Shares Spike Higher
10 months ago
Quick Summary
U.S. stocks declined mid-session, with the Dow Jones index down over 400 points on Monday.
Why It Matters
A significant decline in the Dow Jones signals market volatility and potential investor concern, impacting sentiment and investment strategies.
Source: Benzinga
Market Sentiment:
Neutral
Quick Summary
In a Phase 1 trial, MB-101 showed good tolerance, with 50% of patients achieving stable disease or better, including two partial and two complete responses lasting up to 66 months.
Why It Matters
Positive Phase 1 trial results for MB-101 indicate potential for effective cancer treatment, boosting investor confidence and interest in the biotech company's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mustang Bio's stock rose 180% following FDA Orphan Drug designation for its brain cancer therapy, MB-101, targeting two rare brain tumor types.
Why It Matters
Mustang Bio's 180% surge reflects significant investor interest following FDA Orphan Drug status for MB-101, potentially enhancing market value and future revenue from rare brain tumor treatments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Mustang Bio, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement, as per Nasdaq Listing Rule 5550(b)(1).
Why It Matters
Mustang Bio's compliance with Nasdaq's equity requirements boosts investor confidence, potentially stabilizing its stock and attracting more institutional interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Mustang Bio, Inc. has exited its manufacturing lease in Worcester, MA, and sold fixed assets to AbbVie for $1 million, focusing on cell therapies for challenging cancers.
Why It Matters
Mustang Bio's lease exit and asset divestment indicate strategic shifts, potentially affecting cash flow and operational focus, which can influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MBIO Stock
What is Mustang Bio Inc.'s (MBIO) stock forecast for 2026?
Analyst forecasts for Mustang Bio Inc. (MBIO) are not currently available. The stock is trading at $0.70.
Is MBIO stock a good investment in 2026?
According to current analyst ratings, MBIO has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MBIO stock?
Price predictions from Wall Street analysts for MBIO are not currently available. The stock is trading at $0.70.
What is Mustang Bio Inc.'s business model?
The company generates revenue through the development and commercialization of proprietary cell and gene therapies, specifically focusing on CAR-T cell therapies and gene therapies. Mustang Bio collaborates with academic institutions and research partners to enhance its R&D efforts, which supports its pipeline of targeted treatments for various cancers and genetic diseases.
What is the highest forecasted price for MBIO Mustang Bio Inc.?
Price targets from Wall Street analysts for MBIO are not currently available. The stock is trading at $0.70.
What is the lowest forecasted price for MBIO Mustang Bio Inc.?
Price targets from Wall Street analysts for MBIO are not currently available. The stock is trading at $0.70.
What is the overall MBIO consensus from analysts for Mustang Bio Inc.?
The overall analyst consensus for MBIO is bullish. Out of 5 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are MBIO stock price projections?
Stock price projections, including those for Mustang Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 3:16 AM UTC